Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Single Inhaler Triple Therapy vs Multiple Inhaler Therapy in COPD
NCT03478683Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 4 trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Jun 2018; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03478683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478683.